Steve Seedhouse

Stock Analyst at Cantor Fitzgerald

(3.90)

# 655

Out of 5,133 analysts

11

Total ratings

70%

Success rate

10.22%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - Specialty & Generic

Stocks Rated by Steve Seedhouse

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	WVE Wave Life Sciences	Maintains: Overweight	$12 → $34	$13.91	+144.43%	1	Dec 9, 2025
	BLTE Belite Bio	Assumes: Overweight	$154	$155.36	-0.88%	1	Nov 24, 2025
	KRRO Korro Bio	Downgrades: Neutral	n/a	$8.94	-	1	Nov 13, 2025
	XNCR Xencor	Maintains: Overweight	$40 → $42	$14.17	+196.40%	2	Nov 6, 2025
	INVA Innoviva	Maintains: Overweight	$29 → $31	$19.43	+59.55%	2	Nov 6, 2025
	CAMP Camp4 Therapeutics	Initiates: Overweight	$7	$6.04	+15.89%	1	Oct 2, 2025
	APLS Apellis Pharmaceuticals	Maintains: Overweight	$39 → $40	$23.20	+72.41%	1	Aug 1, 2025
	TVRD Tvardi Therapeutics	Initiates: Overweight	$52	$4.49	+1,058.13%	1	Jul 11, 2025
	HROW Harrow	Initiates: Overweight	$76	$47.84	+58.86%	1	Jul 11, 2025

Wave Life Sciences

Dec 9, 2025

Maintains: Overweight

Price Target: $12 → $34

Current: $13.91

Upside: +144.43%

Belite Bio

Nov 24, 2025

Assumes: Overweight

Price Target: $154

Current: $155.36

Upside: -0.88%

Korro Bio

Nov 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $8.94

Upside: -

Xencor

Nov 6, 2025

Maintains: Overweight

Price Target: $40 → $42

Current: $14.17

Upside: +196.40%

Innoviva

Nov 6, 2025

Maintains: Overweight

Price Target: $29 → $31

Current: $19.43

Upside: +59.55%

Camp4 Therapeutics

Oct 2, 2025

Initiates: Overweight

Price Target: $7

Current: $6.04

Upside: +15.89%

Apellis Pharmaceuticals

Aug 1, 2025

Maintains: Overweight

Price Target: $39 → $40

Current: $23.20

Upside: +72.41%

Tvardi Therapeutics

Jul 11, 2025

Initiates: Overweight

Price Target: $52

Current: $4.49

Upside: +1,058.13%

Harrow

Jul 11, 2025

Initiates: Overweight

Price Target: $76

Current: $47.84

Upside: +58.86%